相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BRAF Inhibitor Unveils Its Potential against Advanced Melanoma
Adina Vultur et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
Karin Schad et al.
CLINICAL CANCER RESEARCH (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Zita Dubauskas et al.
CLINICAL GENITOURINARY CANCER (2009)
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Jean Philippe Arnault et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
David S. Hong et al.
ARCHIVES OF DERMATOLOGY (2008)
Sorafenib-induced eruptive melanocytic lesions
Heidi H. Kong et al.
ARCHIVES OF DERMATOLOGY (2008)
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2008)
Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization
Ole Petter F. Clausen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors?
C Robert et al.
ANNALS OF INTERNAL MEDICINE (2005)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Tyrosine kinase inhibition and grey hair
C Robert et al.
LANCET (2003)
Persistent p53 mutations in single cells from normal human skin
G Ling et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
分享论文
